CardioAktiv Taurine, tablets 500 mg 60 pcs

Pharmacotherapeutic group: metabolic agent.

ATC code: C01EB

Pharmacological properties

Pharmacodynamics

Taurine is a natural product of metabolism of sulfur-containing amino acids: cysteine, cysteamine, methionine. Taurine has osmoregulatory and membrane-protective properties, has a positive effect on the phospholipid composition of cell membranes, normalizes the exchange of calcium and potassium ions in cells.

Taurine shows properties of inhibitory neurotransmitter. It has anti-stressor effect and may regulate release of gamma-aminobutyric acid (GABA), adrenaline, prolactin and other hormones and regulate responses to them.

Involving in the synthesis of respiratory chain proteins in the mitochondria, taurine regulates oxidative processes and exhibits antioxidant properties and affects enzymes, such as cytochromes, involved in the metabolism of various xenobiotics.

Taurine improves metabolic processes in the heart, liver and other organs and tissues. In chronic diffuse liver disease taurine increases blood flow and reduces the severity of cytolysis.

The treatment with the preparation CardioAktiv® Taurine in case of cardiovascular failure (CVF) leads to the decrease of congestion in the small and large circulatory system: intracardiac diastolic pressure decreases, myocardial contractility increases (maximum contraction and relaxation rate, contractility and relaxation indices).

The drug moderately decreases blood pressure (BP) in patients with arterial hypertension and has almost no effect on BP in patients with cardiovascular insufficiency with reduced BP.

CardioAktiv^® Taurine reduces side effects from overdose of cardiac glycosides and slow calcium channel blockers; reduces hepatotoxicity of antifungal drugs. Improves performance under heavy physical exertion.

In diabetics, approximately 2 weeks after starting to take CardioActive^® Taurine reduces blood glucose concentrations. There is also a significant decrease in triglyceride concentration and, to a lesser extent, in cholesterol concentration, reduction of plasma atherogenicity of lipids. With long-term use of the drug (about 6 months) improvement of the microcirculatory blood flow in the eye was noted.

Pharmacokinetics

After a single oral administration of 500 mg of the preparation KardioAktiv^® Taurine, the active substance taurine is determined in blood in 15-20 minutes, reaching the maximum value in 1.5-2 hours. The drug is completely eliminated after 24 hours.

Indications

The drug is used in the complex therapy:

• cardiovascular insufficiency of various etiology;
• intoxication caused by taking cardiac glycosides;
• sugar diabetes type 1;
• sugar diabetes type 2, including moderate hypercholesterolemia.

.

Active ingredient

Taurine

Composition

Composition per tablet

Active ingredient: taurine – 500 mg.

Ancillary components:

povidone – 57.0 mg,

microcrystalline cellulose – 18.0 mg,

croscarmellose sodium – 17.2 mg,

calcium stearate – 4.8 mg,

colloidal silicon dioxide – 3.0 mg.

How to take, the dosage

Consult a physician before using the drug.

In case of heart failure, CardioActive Taurine is taken orally at 250-500 mg (1/2 to 1 tablet) 2 times a day 20 minutes before meals, the course of treatment is 30 days.

The dose can be increased to 2-3 g (4-6 tablets) per day.

In intoxication with cardiac glycosides, at least 750 mg (1.5 tablets) per day.

In case of type 1 diabetes mellitus, 500 mg (1 tablet) 2 times a day in combination with insulin therapy for 3-6 months.

In type 2 diabetes mellitus, 500 mg (1 tablet) 2 times daily in combination with diet therapy or other oral hypoglycemic agents.

In type 2 diabetes, including moderate hypercholesterolemia, 500 mg (1 tablet) 2 times daily.

Interaction

CardioActive Taurine can be used with other medicines.

Taurine increases the inotropic effect of cardiac glycosides.

Special Instructions

With caution use in patients with severe renal dysfunction, concomitant use with cardiac glycosides, slow calcium channel blockers (CCBs).

Contraindications

Serious decompensated heart failure.

Hypersensitivity to the drug.

CardioActive^® Taurine is not recommended for use in children under 18 years of age due to insufficient efficacy and safety data.

Side effects

Allergic reactions to the ingredients of the drug are possible.

Overdose

There are no data on overdose.

Pregnancy use

It is not recommended to use CardioAktiv® Taurine during pregnancy and breastfeeding because of lack of sufficient experience in clinical use of this category of patients.

Similarities

Taufon, Dibicor, Taurine, Taurine Renewal, Taustin